Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Silence Therapeutics (SLN) Gains from Sales and Divestitures (2019 - 2021)

Historic Gains from Sales and Divestitures for Silence Therapeutics (SLN) over the last 1 years, with Q4 2019 value amounting to $2571.4.

  • Silence Therapeutics' Gains from Sales and Divestitures changed N/A to $2571.4 in Q4 2019 from the same period last year, while for Dec 2019 it was $2571.4, marking a year-over-year change of. This contributed to the annual value of $2553.7 for FY2019, which is N/A changed from last year.
  • Per Silence Therapeutics' latest filing, its Gains from Sales and Divestitures stood at $2571.4 for Q4 2019.
  • Silence Therapeutics' 5-year Gains from Sales and Divestitures high stood at $2571.4 for Q4 2019, and its period low was $1286.3 during Q2 2019.